Monograph Details
|
|
Cardiovascular System
> Angina
|
|
PROCARDIA |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Calcium channel blocker (dihydropyridine). |
| Generic Name |
|
Nifedipine 10mg, 20mg; caps. |
| Indications |
|
Vasospastic and chronic stable angina. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 10mg three times daily, titrate over 7–14 days (for faster titration: see literature). Usual range 10–20mg three times daily; max 30mg/dose and 180mg/day. |
| Precautions |
|
Aortic stenosis. Severe obstructive coronary artery disease. Heart failure. GI narrowing (tabs). Monitor blood pressure initially and during titration. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Hypotension, angina, and heart failure possible with β-blockers. Potentiated by cimetidine, grapefruit juice. Potentiates antihypertensives, digoxin. Hypotension possible with fentanyl. Monitor oral anticoagulants, quinidine. |
| Adverse Reactions |
|
Edema, headache, fatigue, dizziness, constipation, nausea, palpitations, muscle cramps; rare: increased angina, acute MI. |
| How Supplied |
Tabs 30mg, 60mg—100, 300
Tabs 90mg—100
Caps 10mg—100, 300
Caps 20mg—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
